Metabolic
Retatrutide
LY-3437943 · triple-G
The most-searched gray-market 'research peptide' of 2026. Phase-3 TRIUMPH-1 topline (21 May 2026): 28.3% weight loss at 12 mg / 80 wk (efficacy estimand; ~25% treatment-regimen).
Evidence
Bhuman trials
Status
Investigationalas of 2026-06
Approval
Not approved
Category
Metabolic
Route
Subcutaneous
Demand rank
#3 most-searched
01Dosing & Protocol
Typical · reference only
Trial targets 4/9/12 mg weekly; community typically settles 4-8 mg weekly, starts far lower (0.25-0.5 mg)
Titration
Reconstitution — illustrative, not a recommendation
10 mg vial + 1 mL BAC = 10 mg/mL; 1 mg = 10 U; 12 mg = 120 U (exceeds 100-U syringe). Valid only if vial truly contains labeled mg.
Reconstitution calculatorlive tool
10units
on a U-100 syringedraw to the 10 mark
Concentration10 mg/mL
Draw volume0.1 mL
Illustrative, not a recommendation. mg vs mcg confusion drives 5–1000× overdoses — always recompute for your own vial and syringe.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Not approved; est. filing Q4'26-Q1'27. Gray-market 'research' vials are unapproved-new-drug territory.
Pre-clinical
Phase 1
Phase 2
Phase 3
Approved
Status
Investigational
503A bulks
Not on the bulks list
Category 2
n/a (investigational; cannot be compounded)
PCAC review
none scheduled
WADA
Not listed
03Evidence — the honest read
What the evidence actually shows
Late Phase 3 topline (company press release; not peer-reviewed). Dose-dependent dysesthesia (~21% high dose); cardiac arrhythmia signal in Phase 2.
04Safety
Contraindications
- MTC/MEN-2 (class-extrapolated)
- Pregnancyhard stop
- Pancreatitis history
Key interactions
- Insulin/sulfonylureas -> hypoglycemia (it LOWERS glucose net; glucagon arm offset by GLP-1/GIP)
- Anesthesia -> aspiration
Serious signals
- Dysesthesia at high dose
- Cardiac arrhythmia imbalance (Phase 2)
- Elevated HR
Monitoring
Glucose/HbA1c; HR; hold before surgery.
05Related in Metabolic
Semaglutide
FDA-approved RCTs
grade A →Tirzepatide
FDA-approved RCTs
grade A →Cagrilintide / CagriSema
human trials
grade B →MOTS-c
animal-only
grade D →06Sources
The primary sources behind this monograph — each opens the registry so you can verify the claim yourself. Last verified 2026-06-13.
SecondaryTRIUMPH-1 trial — via ajmc.comTrial coverage (secondary → registry) · TRIUMPH-1How we source & verify — the full method →Beyond these primaries, every monograph is distilled from TrackurStack’s research dossier — 584 de-duplicated sources across 4 research iterations, adversarially verified against primary sources.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: high (trial data) / low (gray-market dosing)